12:00 AM
 | 
Oct 19, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Nicotine-Qbeta: Interim Phase II data

Interim data from a double-blind Phase II trial in 200 cigarette smokers showed that repeated administrations of 100 µg NIC002 missed the primary endpoint of continuous abstinence from smoking from weeks 8 to 12 after start of treatment vs. placebo. Cytos said the vaccine failed to induce "sufficiently high" antibody titers, which may have led to the...

Read the full 263 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >